| Next-generation proteasome inhibitors for cancer therapy JE Park, Z Miller, Y Jun, W Lee, KB Kim Translational Research 198, 1-16, 2018 | 124 | 2018 |
| Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors H Hyun, J Park, K Willis, JE Park, LT Lyle, W Lee, Y Yeo Biomaterials 180, 206-224, 2018 | 121 | 2018 |
| A Comparative In Vivo Study of Albumin‐Coated Paclitaxel Nanocrystals and Abraxane J Park, JE Park, VE Hedrick, KV Wood, C Bonham, W Lee, Y Yeo Small 14 (16), 1703670, 2018 | 53 | 2018 |
| Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation JE Park, J Park, Y Jun, Y Oh, G Ryoo, YS Jeong, HH Gadalla, JS Min, ... Journal of Controlled Release 302, 148-159, 2019 | 44 | 2019 |
| Enhancing docetaxel delivery to multidrug-resistant cancer cells with albumin-coated nanocrystals SF Gad, J Park, JE Park, GN Fetih, SS Tous, W Lee, Y Yeo Molecular pharmaceutics 15 (3), 871-881, 2018 | 31 | 2018 |
| Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase InhibitorsEpigenetic IGF2 Deregulation … HY Min, SC Lee, JK Woo, HJ Jung, KH Park, HM Jeong, SY Hyun, J Cho, ... Clinical Cancer Research 23 (5), 1299-1311, 2017 | 31 | 2017 |
| Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer OS Kwon, H Lee, HJ Kong, EJ Kwon, JE Park, W Lee, S Kang, M Kim, ... Oncogene 39 (23), 4567-4580, 2020 | 28 | 2020 |
| Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice JE Park, SE Chun, D Reichel, JS Min, SC Lee, S Han, G Ryoo, Y Oh, ... PloS one 12 (3), e0173247, 2017 | 25 | 2017 |
| The N-terminal region of organic anion transporting polypeptide 1B3 (OATP1B3) plays an essential role in regulating its plasma membrane trafficking SE Chun, N Thakkar, Y Oh, JE Park, S Han, G Ryoo, H Hahn, SH Maeng, ... Biochemical pharmacology 131, 98-105, 2017 | 24 | 2017 |
| Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to carfilzomib and bortezomib MJ Lee, D Bhattarai, J Yoo, Z Miller, JE Park, S Lee, W Lee, JJ Driscoll, ... Journal of medicinal chemistry 62 (9), 4444-4455, 2019 | 23 | 2019 |
| H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth MJ Lee, Z Miller, JE Park, D Bhattarai, W Lee, KB Kim Scientific Reports 9 (1), 4089, 2019 | 16 | 2019 |
| A FRET-based approach for identification of proteasome catalytic subunit composition JE Park, Y Wu, KC Carmony, Z Miller, LK Sharma, DM Lee, DY Kim, ... Molecular BioSystems 10 (2), 196-200, 2014 | 16 | 2014 |
| PSMB9 Codon 60 Polymorphisms Have No Impact on the Activity of the Immunoproteasome Catalytic Subunit B1i Expressed in Multiple Types of Solid Cancer JE Park, L Ao, Z Miller, K Kim, Y Wu, ER Jang, EY Lee, KB Kim, W Lee PLoS One 8 (9), e73732, 2013 | 13 | 2013 |
| Alternative splicing: expanding diversity in major ABC and SLC drug transporters JE Park, G Ryoo, W Lee The AAPS Journal 19, 1643-1655, 2017 | 12 | 2017 |
| Inhibition of organic anion transporting polypeptide 1B1 and 1B3 by betulinic acid: effects of preincubation and albumin in the media Y Oh, YS Jeong, MS Kim, JS Min, G Ryoo, JE Park, Y Jun, YK Song, ... Journal of pharmaceutical sciences 107 (6), 1713-1723, 2018 | 11 | 2018 |
| Silicon switch approach in TRPV1 antagonist MK-056 and its analogues M Chang, SR Park, J Kim, M Jang, JH Park, JE Park, HG Park, YG Suh, ... Bioorganic & medicinal chemistry 18 (1), 111-116, 2010 | 11 | 2010 |
| Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity‐Based Probes K Cornish Carmony, LK Sharma, DM Lee, JE Park, W Lee, KB Kim ChemBioChem 16 (2), 284-292, 2015 | 9 | 2015 |
| Transient, tunable expression of NTCP and BSEP in MDCKII cells for kinetic delineation of the rate-determining process and inhibitory effects of rifampicin in hepatobiliary … S Ito, W Lee, JE Park, M Yasunaga, A Mori, S Ohtsuki, Y Sugiyama Journal of Pharmaceutical Sciences 110 (1), 365-375, 2021 | 8 | 2021 |
| Quantitative determination of carfilzomib in mouse plasma by liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic study JS Min, J Kim, JH Kim, D Kim, YF Zheng, JE Park, W Lee, SK Bae Journal of Pharmaceutical and Biomedical Analysis 146, 341-346, 2017 | 7 | 2017 |
| Improved prediction of the drug-drug interactions of Pemafibrate caused by cyclosporine a and rifampicin via PBPK MODELING: Consideration of the albumin-mediated hepatic uptake … JE Park, Y Shitara, W Lee, S Morita, J Sahi, K Toshimoto, Y Sugiyama Journal of Pharmaceutical Sciences 110 (1), 517-528, 2021 | 5 | 2021 |
